Patent applications published 26 January 2011
Selected patent applications from the weekly European Patents Bulletin
- Substituted tetracycline compounds
Paratek Pharmaceuticals 2276342*
- Antimicrobial agent, method of preparing an antimicrobial agent and articles containing the same
University of Florida Research Foundation 2276343*
- Methods for reducing lipid absorption by an animal
Nestec 2276344*
- Small-molecule inhibitors of the androgen receptor
The Regents of the University of California 2276345*
- Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
National Health Research Institutes, Taiwan 2276346*
- Toltrazuril with improved dissociation properties
KRKA 2276347*
- Liquid buffered GDF-5 formulations
Advanced Technologies and Regenerative Medicine 2276458*
- Sulindac formulations in a biodegradable material
Medtronic 2276459*
- Device for in situ production and topical administration of allicin
Yeda Research and Development Company at the Weizmann Institute of Science 2276460*
- Pharmaceutical formulation containing palmitoyl ethanolamide and stearoyl ethanolamide
Vermont Italia 2276461*
- Ophthalmic solutions displaying improved efficacy
Johnson & Johnson Vision Care 2276462*
- Diterpene glycosides as natural solubilisers
Board of Supervisors of Louisiana State University 2276463*
- Combinations of antiviral agents and other compounds
Mallinckrodt 2276464*
- Extended release formulations containing a wax
Mylan Pharmaceuticals 2276465*
- Granulate comprising escitalopram oxalate
Hexal 2276466*
- Alpha and beta adrenergic receptor agonists for treatment of pain and/or inflammation
Warsaw Orthopedic 2276467*
- Demulsifiers and methods for use in pharmaceutical applications
Rhodia Operations 2276468*
- Alpha adrenergic receptor agonists for treatment of degenerative disc disease
Warsaw Orthopedic 2276469*
- Alpga adrenergic receptor agonists for treatment of pain and/or inflammation
Warsaw Orthopedic 2276470*
- Composite lacrimal insert and related methods
QLT Plug Delivery 2276471*
- Compsns comprising weakly basic drugs and controlled release dosage forms
Eurand 2276472*
- Carbidopa/lipodopa gastroretentive drug delivery
Intec Pharma 2276473*
- Solid oral form with dual release profile, containing multiparticulates
Flamel Technologies 2276474*
- Biodegradable nanoshells for delivery of therapeutic and/or imaging molecules
National University if Ireland, Galway 2276475*
- Manufacturing method of thermo-rod for active drug release, and the thermo-rod
Korea Sangsa 2276476*
- Self-destructing transdermal therapeutic system having improved functionality and efficacy
LTS Lohmann Therapie-Systeme 2276477*
- Methods of administering prostratin structural analogues thereof
Aids Research Alliance 2276478*
- Prodrugs of neuraminidase inhibitors
TSRL 2276479*
- Calycosin and analogues thereof for the treatment of oestrogen receptor beta-mediated diseases
Bionovo 2276480*
- Use of nenzo-fused heterocycle sulphamide derivatives for the treatment of anxiety
Janssen Pharmaceutica 2276481*
- HSP90 inhibitors or modulators for treatment or prevention of substance-related disorders
The Regents of the University of California 2276482*
- Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsunphonylethyl]-4-acetylaminoisoindoline-1,3-dione, compsns thereof, and uses thereof
Celgene 2276483*
- An antimicrobial compsn
Institute of Technology Sligo 2276484*
- Use of epothelone D in treating tau-associated diseases including Alzheimer’s disease
Bristol-Myers Squibb 2276486*
- Novel substituted imidazoquinolines
4SC 2276486*
- Piperlongumine and piperlongumine analogues for use in the treatment of cancer
The General Hospital Corp 2276487*
- 5-imidazoquinolines as pyramidine derivatives as potent modulators of VEGF-driven angiogenic processes
Novartis 2276488*
- Pterin-based therapies for inflammatory conditions
Sanrx Pharmaceuticals 2276489*
- Novel (pyrroloquinoxalinyl) pyrazinecarbohydrazide-oxalic acid co-crystal for treatment of cancer and other diseases
Novelix Pharmaceuticals 2276490*
- New form of therapy for irritable bowel syndrome
Karolinska Institutet Innovations 276491*
- Sustained release delivery of active agents to treat glaucoma and ocular hypertension
QLT Plug Delivery 2276492*
- Antioxidant inflammation modulators:oleanolic acid derivatives with amino and other modifications at C-17
Reata Pharmaceuticals 2276493*
- Stable aqueous compsns comprising bioactive creatine species
Owoc, John 2276494*
- Stimulation of an immune response by enantiomers of cationic lipids
PDS Biotechnology 2276495*
- Therapeutic modulation of ocular surface lubrication
The Regents of the University of California; Schepens Eye Research Institute 2276496*
- Ophthalmic device and method of use thereof, for increasing ocular boundary lubrication
The Regents of the University of California; Schepens Eye Research Institute 2276497*
- Use of probiotic bacteria for the treatment of hyperhomocysteinaemia
Probiotical 2276498*
- Recombinant deamidated gliadin antigen
Bio-Rad Laboratories 2276499*
- Reactivation of axon growth and recovery in chronic spinal cord injury
Yale University 2278500*
- Methods and compsns for genetic and retinal disease
Drenser, Kimberley 2276501*
- Compsns for the prevention and treatment of neuroinjury and methods of use thereof
Morehouse School of Medicine 2276502*
- Citrullinated cytokines
Katholieke Universiteit Leuven 2276503*
- Vascular ageing inhibitor and anti-aging formulation
Ishii, Hikaru 2276504*
- Use of a substance for manufacturing a medicament for treatment of the common cold
Tano, Krister 2276505*
- Potent conjugates and hydrophilic linkers
Immunogen 2276506*
- Chimeric porcine circovirus PCV2Gen-1Rep and uses thereof
Virginia Tech Intellectual Properties 2276507*
- Delivery of LFA-1 antagonists to the gastrointestinal system
Sarcode Corp 2276508*
- Detection and treatment of pancreatic, ovarian, and other cancers
Seattle Genetics 2276509*
- Chemical and biochemical adducts as biomarkers for organophosphate exposure
Human Biomolecular Research Institute 2276510*
- Compsns and methods for delivering inhibitory oligonucleotides
Government of the United States of America, as represented by the Secretary, Department of Health and Human Services 2276511*